BAXTER, CENTEON TO STOP "RE-POOLING" PLASMA IN EFFORT TO REDUCE PLASMA POOL SIZE FOR BLOOD PRODUCTS, FIRMS TELL SHAYS SUBCOMMITTEE; FDA SEEKING UPPER LIMIT
Executive Summary
Baxter will no longer "re-pool" plasma material in its blood product manufacturing operations in an effort to reduce the number of donors represented in any one lot of product and to facilitate tracking of donors, the company told Rep. Shays' (R-Conn.) Government Reform/Human Resources Subcommittee July 31.